Format

Send to

Choose Destination
Gastroenterol Clin North Am. 2016 Mar;45(1):29-43. doi: 10.1016/j.gtc.2015.10.005.

Autoimmune Pancreatitis: An Update on Diagnosis and Management.

Author information

1
Yale-Waterbury Internal Medicine Residency Program, Yale University School of Medicine, New Haven, CT 06510, USA.
2
Yale Center for Pancreatic Disease, Section of Digestive Disease, Yale University, LMP 1080, 15 York Street, New Haven, CT 06510, USA. Electronic address: james.j.farrell@yale.edu.

Abstract

There is an evolving understanding that autoimmune pancreatitis (AIP) is an immunoglobulin (Ig) G4 systemic disease. It can manifest as primarily a pancreatic disorder or in association with other disorders of presumed autoimmune cause. Classic clinical characteristics include obstructive jaundice, abdominal pain, and acute pancreatitis. Thus, AIP can be difficult to distinguish from pancreatic malignancy. However, AIP may respond to therapy with corticosteroids, and has a strong association with other immune mediated diseases. Although primarily a pathologic diagnosis, attempts have been made to reliably diagnose AIP clinically. AIP can be classified as either type 1 or type 2.

KEYWORDS:

Autoimmune pancreatitis; Corticosteroids; Idiopathic duct-centric pancreatitis; IgG4; International Consensus Diagnostic Criteria; Lymphoplasmacytic sclerosing pancreatitis

PMID:
26895679
DOI:
10.1016/j.gtc.2015.10.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center